ArticleFrontiers in oncology2025
TCR and BCR repertoire analysis reveals distinct signatures between benign and malignant ovarian tumors.
Article in Frontiers in oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- T-cell receptor therapy in ovarian cancer: concepts and challenges.Journal of ovarian research · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The immune system is of paramount importance in maintaining human health and defending against pathogens. Among them, the adaptive immune system is a crucial component of the immune system, as it is responsible for generating and modulating the immune repertoire, which is vital for immune responses. Methods: We conducted a comprehensive analysis of T cell receptor (TCR) and B cell receptor (BCR) clonotypes in the peripheral blood immune repertoire of 20 patients with benign and malignant ovarian tumors. The analysis elucidates the differences between the two immune repertoires in various aspects and constructs an early screening machine learning model for ovarian tumors based on the characteristics of the immune repertoire. Result: The finding revealed that patients with malignant ovarian tumors exhibited a reduction in balance, richness, and diversity in their immune repertoires compared to those with benign tumors. Additionally, there was a negative correlation between patient age and immune repertoire diversity, and the immune repertoire of patients with malignant tumors displayed high heterogeneity. By employing machine learning techniques, we have developed an early screening model based on 16 TCR V-J genes and 11 BCR V-J genes, which achieved an average AUC of 0.93 (TCR) and 0.958 (BCR) on the ovarian tumor test dataset. Moreover, a comparison of the spatial distributions of TCR and BCR revealed, for the first time, that TCR was more significantly associated with the benign-to-malignant transformation of ovarian tumors. Conclusions: Our study highlights the critical role of the adaptive immune repertoire in distinguishing between benign and malignant ovarian tumors. TCR demonstrated more distinct spatial distribution patterns between benign and malignant states, suggesting its potential as a more sensitive biomarker for ovarian tumor detection. These findings provide new insights into the immunological landscape of ovarian tumors and offer a promising avenue for early diagnosis and prognosis assessment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.